Treatment of bipolar disorder in pediatric population

Weronika Pawlak-Łukaszek; Martyna Bień; Lena Cichoń; Małgorzata Janas-Kozik

doi:10.5114/fpn.2025.160138

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Standardy etyczne i procedury Recenzenci Zasady publikacji prac

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

Otwarty dostęp

2/2025
vol. 41

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł przeglądowy

Leczenie choroby afektywnej dwubiegunowej w populacji pediatrycznej

Weronika D. Pawlak-Łukaszek

¹

,

Martyna P. Bień

^{1, 2}

,

Lena Cichoń

^{1, 2}

,

Małgorzata Janas-Kozik

^{1, 2}

The John Paul II Child and Family Health Centre in Sosnowiec Ltd., Sosnowiec, Poland; Centrum Zdrowia Dziecka i Rodziny im. Jana Pawła II w Sosnowcu Sp. z o.o., Sosnowiec, Polska
Department and Clinical Unit of Psychiatry and Psychotherapy of Developmental Age, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland; Katedra i Oddział Kliniczny Psychiatrii i Psychoterapii Wieku Rozwojowego, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska

Farmakoterapia w Psychiatrii i Neurologii 2025

DOI: https://doi.org/10.5114/fpn.2025.160138

Data publikacji online: 2026/04/28

Plik artykułu:

- Treatment of bipolar disorder in paediatric population.pdf [0.57 MB]

Pobierz cytowanie

Metryki PlumX:

1. Arypiprazol. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/34036/characteristic.

2. Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017; 27: 865–876.

3. Chokhawala K, Lee S, Saadabadi A. Lithium. National Center for Biotechnology Information. National Library of Medicine 2024; (dostęp 18.11.2025).

4. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 298–304.

5. Cichon L, Janas-Kozik M, Siwiec A, Rybakowski JK, Cichon L, Janas-Kozik M, et al. Clinical picture and treatment of bipolar affective disorder in children and adolescents. Psychiatr Pol 2020; 54 (1): 35–50.

6. Colom F, Vieta E. Podręcznik psychoedukacji w zaburzeniach afektywnych dwubiegunowych. Warszawa: Medipage, 2009.

7. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. BipolarDisord 2009; 11 (5): 483–493.

8. DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry 2017; 56 (12): 1015–1025.

9. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K, Nosaka T et al. Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. J Am Acad Child Adolesc Psychiatry 2022; 61 (2): 243–254.

10. DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. J Child Adolesc Psychopharmacol 2021; 31 (7): 494–503.

11. Findling RL, Çavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK et al. Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder. J Child Adolesc Psychopharmacol 2013; 23 (8): 545.

12. Findling RL, Landbloom RL, Mackle M, Wu Xiao, Snow-AdamiSnow-Adami L, Chang K. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. Paediatr Drugs 2016; 18 (5): 367–378.

13. Findling RL, Earley W, Suppes T, Patel M, Wu X, Chang CT et al. Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: Efficacy related to mixed or manic episode, stage of illness, and body weight. Neuropsychiatr Dis Treat 2018; 14: 1941–1952. (a)

14. Findling RL, Stepanova E, Youngstrom EA, Young AS. Progress in diagnosis and treatment of bipolar disorder among children and adolescents: An international perspective. Evid Based Ment Health 2018; 21 (4): 177–181. (b)

15. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. International Journal of Neuropsychopharmacology 2016 Feb 1; 20 (2): 180–195.

16. Fristad MA, MacPherson HA. Evidence-Based Psychosocial Treatments for Child and Adolescent Bipolar Spectrum Disorders. J Clin Child Adolesc Psychol 2014; 43 (3): 339–55.

17. Fristad MA, Verducci JS, Walters K, Young ME. Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders. Arch Gen Psychiatry 2009; 66 (9): 1013–1021.

18. Goldstein BI, Birmaher B, Carlson GA, DelBello MP, Findling RL, Fristad M et al. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disord 2017; 19 (7): 524–543.

19. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30 (6): 495–553.

20. Grabski B, Mączka G, Dudek D. The role of psychoeducation in the complex treatment of bipolar disorder. Arch Psychiatry Psychother 2007; 9 (3): 35–41.

21. Guidelines. Valproate – reproductive risks. Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm. 2025;

22. https://www.gov.uk/guidance/valproate-reproductive-risks (dostęp 18.11.2025).

23. Janas-Kozik M, Wolańczyk (red. nauk.). Psychiatria Dzieci i Młodzieży. PZWL Wydawnictwo Lekarskie, Warszawa 2023.

24. Joshi G, Petty C, Wozniak J, Faraone SV, Spencer AE, Woodworth KY et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology 2013 Feb; 227 (3): 449–458.

25. Keramatian K, Chakrabarty T, Saraf G, Yatham LN. New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials. Curr Psychiatry Rep 2021; 23 (7).

26. Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD Guidelines for the treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus: Journal of Life Long Learning in Psychiatry 2023; 21 (4): 344–353.

27. Lewandowska A, Janas-Kozik M, Tyszkiewicz-Nwafor M, Dudek D, Gałecki P, Remberk B. Zaburzenie dwubiegunowe u dzieci, młodzieży i młodych dorosłych. Część 2. Rekomendacje pod patronatem Zarządu Głównego Polskiego Towarzystwa Psychiatrycznego oraz Konsultantów Krajowych w dziedzinie psychiatrii i psychiatrii dzieci i młodzieży; Psychiatr Pol 2025; 59 (3): 359–372.

28. Lithium carbonicum. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/3943/characteristic.

29. Lorafen. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/3971/characteristic/.

30. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacother 2004; 24 (9): 1177–1185.

31. Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60 (9): 904–912.

32. Miklowitz DJ, Taylor DO. Bipolar Disorder in Childhood and Adolescence. Handb Depress Adolesc 2008; 26 (Suppl 3): 179–205.

33. Nandagopal JJ, DelBello MP, Kowatch R. Pharmacologic Treatment of Pediatric Bipolar Disorder. Child Adolesc Psychiatr Clin N Am 2009; 18 (2): 455–469.

34. National Institute of Health and Care Excellence, CG185; https://www.nice.org.uk/guidance/cg185.

35. National Institute of Health and Care Excellence, TA292; https://www.nice.org.uk/guidance/ta292.

36. Neorelium. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/5775/characteristic.

37. O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005: 66 Suppl 2: 28–33.

38. Paliperidone +pharma. Charakterystka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/50584/characteristic (dostęp 15.12.2025).

39. Patel NC, DelBello MP, Bryan HS, Adler CM, Kowatch RA, Stanford K et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 289–297.

40. Poweleit EA, Colestock M, Kantemneni EC, Strawn JR, Patino LR, DelBello MP et al. Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. J Child Adolesc Psychopharmacol 2020; 30 (4): 267–272.

41. Riccobene T, Riesenberg R, Yeung PP, Earley WR, Hankinson AL. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia. J Child Adolesc Psychopharmacol 2022; 32 (8): 434–443.

42. Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58 (6): 855–863.

43. Singh B, Swartz HA, Cuellar-Barboza AB, Schaffer A, Kato T, Dols A, Sperry SH, Vassilev AB, Burdick KE, Frye MA. Bipolar disorder. The Lancet 2025; 406 (10506): 963–978.

44. Singh MK, Pikalov A, Siu C, Tocco M, Loebel A. Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial. J Child Adolesc Psychopharmacol 2020; 30 (10): 590–598.

45. Stepanova E, Grant B, Findling RL. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. Pediatr Drugs 2018; 20 (2): 121–34.

46. Szegedi A, Durgam S, Mackle M, Yun Yu S, Wu X, Mathews M et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 2018; 175 (1): 71–79.

47. Taylor DO, Miklowitz DJ. Bipolar Disorder in Childhood and Adolescence. Handb Depress Adolesc 2008; 26 (Suppl 3): 179–205.

48. Vita G, Nöhles VB, Ostuzzi G, Barbui C, Tedeschi F, Heuer FH et al. Systematic Review and Network Meta-Analysis: Efficacy and Safety of Antipsychotics vs Antiepileptics or Lithium for Acute Mania in Children and Adolescents. J Am Acad Child Adolesc Psychiatry 2025; 64 (2): 143–157.

49. Walker DJ, DelBello MP, Landry J, D’Souza DN, Detke HC. Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination. Child Adolesc Psychiatry Ment Health 2017; 11 (1): 1–12.

50. Wozniak J, O’Connor H, Iorini M, Ambrose AJH. Pediatric Bipolar Disorder: Challenges in Diagnosis and Treatment. Pediatric Drugs 2025; 27 (2): 125–142.

51. Zagorski N. FDA Approves Latuda for Bipolar Depression in Children and Adolescents. Psych News 2018; 4 (dostęp 14.12.2025).

52. Zypsila. Charakterystyka produktu leczniczego; https://leki.urpl.gov.pl/files/43_Zypsila_kaps_tw_80mg.pdf (dostęp 02.12.2025).

Leczenie choroby afektywnej dwubiegunowej w populacji pediatrycznej

Weronika D. Pawlak-Łukaszek 1 , Martyna P. Bień 1, 2 , Lena Cichoń 1, 2 , Małgorzata Janas-Kozik 1, 2

Weronika D. Pawlak-Łukaszek

¹

,

Martyna P. Bień

^{1, 2}

,

Lena Cichoń

^{1, 2}

,

Małgorzata Janas-Kozik

^{1, 2}